The Orphan Drug Act, which was enacted in 1983, has been largely responsible for advancing the quality and quantity of rare disease research over the past 40 years. It has... Read More →

The FDA has been advocating for increased diversity in clinical trials for decades, but certain groups remain significantly underrepresented in many studies. For instance Black/African American people are 1.5 to... Read More →

The escalating growth in decentralized clinical trials (DCTs) has brought with it an array of variations as to how these trials are being implemented—all with the goal of better accommodating.... Read More →